SeaStar Medical Holding Corp
Business
SeaStar Medical Holding Corp is a commercial-stage medical device company that develops the Selective Cytopheretic Device (SCD), an extracorporeal therapeutic platform designed to neutralize overactive immune cells and reduce cytokine storms in critically ill patients with organ failure. The company offers QUELIMMUNE, an FDA-approved pediatric SCD therapy for acute kidney injury due to sepsis, and is conducting pivotal trials for adult acute kidney injury and feasibility studies in cardiorenal syndrome. SeaStar markets its SCD therapy in the United States and pursues regulatory designations across multiple acute and chronic inflammatory indications.
Summary from 10-K filed 2026-03-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net revenue | 1 | 135,000 | 0 | — | — | |
| Cost of goods sold | 53,000 | 0 | 0 | — | — | |
| Gross profit | 1 | 135,000 | 0 | — | — | |
| Research and development | 8 | 9 | 6 | 3 | 3 | |
| General and administrative | 6 | 9 | 8 | 7 | 2 | |
| Total operating expenses | 13 | 18 | 14 | 12 | 4 | |
| Loss from operations | −12 | −18 | −14 | −12 | −4 | |
| Interest income | 325,000 | 101,000 | 0 | — | 11,820 | |
| Interest expense | −31,000 | −244,000 | — | — | — | |
| Other financing costs | −298,000 | 0 | — | — | — | |
| Change in fair value of convertible notes | 0 | −6 | — | — | — | |
| Change in fair value of warrants liability | 32,000 | −697,000 | 545,000 | 11 | −27,000 | |
| Total other income (expense), net | 28,000 | −7 | — | — | — | |
| Loss before provision for income taxes | −12 | −25 | −26 | −12 | −5 | |
| Provision for income taxes | 3,000 | 3,000 | 0 | 1,000 | −1,000 | |
| Net loss | −12 | −25 | — | — | — | |
| Net loss per share of common stock, basic and diluted (in dollars per share) | −5.86 | −66.33 | −30.26 | −1.48 | −0.63 | |
| Weighted-average shares outstanding, basic and diluted (in shares) | 2 | 374,356 | 866,813 | 8 | 7 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2023 2023-06-30 |
|---|---|---|---|---|---|---|
| Cash | 12 | 2 | 176,000 | 73,000 | 13,000 | |
| Accounts receivable, net of allowance for credit losses of $3 and $0, respectively | 237,000 | 112,000 | 0 | — | — | |
| Inventory | 66,000 | 0 | — | — | — | |
| Prepaid expenses | 1 | 2 | 2 | 1 | 1 | |
| Total current assets | 14 | 4 | 2 | 1 | 1 | |
| Other assets | 578,000 | 892,000 | — | — | — | |
| Total assets | 14 | 5 | 4 | 3 | 3 | |
| Accounts payable | 948,000 | 3 | 4 | 5 | 4 | |
| Accrued expenses | 2 | 3 | 2 | 2 | 1 | |
| Notes payable, net of deferred financing costs | 525,000 | 574,000 | 565,000 | — | 6 | |
| Liability classified warrants | 1,000 | 33,000 | — | — | — | |
| Total current liabilities | 4 | 7 | 13 | 13 | 14 | |
| Total liabilities | 4 | 7 | 17 | 19 | 14 | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Preferred stock - $0.0001 par value, 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | — | — | |
| Common stock - $0.0001 par value per share; 450,000,000 and 500,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 3,844,613 and 650,639 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 4,000 | 2,000 | 1,000 | 3,000 | 2,000 | |
| Additional paid-in capital | 162 | 137 | 101 | 89 | 86 | |
| Accumulated deficit | −152 | −140 | −115 | −105 | −98 | |
| Total stockholders equity/(deficit) | 10 | −2 | −14 | −16 | −12 | |
| Total liabilities and stockholders equity/(deficit) | 14 | 5 | 4 | 3 | 3 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Amortization of deferred financing costs | 18,000 | 102,000 | — | — | — | |
| Shares issued for the standby equity purchase agreement commitment fee | 298,000 | 0 | — | — | — | |
| Stock-based compensation | 624,000 | 887,000 | 2 | 1 | — | |
| Accounts receivables, net | −125,000 | −112,000 | 0 | — | — | |
| Inventory | −66,000 | 0 | — | 0 | 55,000 | |
| Prepaid expenses | 538,000 | 297,000 | −97,000 | −1 | 12,000 | |
| Other assets | 314,000 | 313,000 | 0 | — | — | |
| Accounts payable | −2 | −1 | 2 | 2 | −297,000 | |
| Accrued expenses | −920,000 | 2 | 517,000 | 2 | — | |
| Other liabilities | 0 | −100,000 | 0 | — | — | |
| Net cash used in operating activities | −14 | −16 | −10 | −8 | −5 | |
| Proceeds from issuance of convertible notes | 0 | 979,000 | 8 | 2 | 3 | |
| Payment of convertible notes | 0 | −700,000 | −400,000 | 0 | — | |
| Proceeds from issuance of shares, net of offering costs | 16 | 17 | 5 | 0 | — | |
| Proceeds from exercise of warrants | 2 | 853,000 | 592,000 | 0 | — | |
| Proceeds from pre-funded warrants | 6 | 4 | — | — | 6 | |
| Proceeds from issuance of notes payable | 767,000 | 713,000 | 800,000 | 2 | 0 | |
| Payment of notes payable | −834,000 | −5 | 0 | −63,000 | 0 | |
| Net cash provided by financing activities | 24 | 18 | 10 | 7 | 3 | |
| Net increase in cash | 10 | 2 | — | — | — | |
| Cash paid for interest | 0 | 553,000 | 1 | 6,000 | 0 | |
| Cash paid for income taxes | 3,000 | 3,000 | 0 | 1,000 | 0 | |
| Exercise of liability classified warrants | 0 | 3 | 0 | — | — | |
| Offering cost incurred but not paid | 0 | 45,000 | 0 | — | — | |
| Issuance of convertible note warrants | 0 | 586,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is SeaStar Medical Holding Corp's CIK number?
SeaStar Medical Holding Corp's SEC CIK number is 0001831868 (1831868). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find SeaStar Medical Holding Corp's SEC filings?
All of SeaStar Medical Holding Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did SeaStar Medical Holding Corp last report earnings?
SeaStar Medical Holding Corp (ICU) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-016726). This is SeaStar Medical Holding Corp's most recent earnings filing of record — not a forecast of its next earnings date.
What is SeaStar Medical Holding Corp's most recent earnings 8-K?
SeaStar Medical Holding Corp's latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001437749-26-016726. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View SeaStar Medical Holding Corp's latest earnings 8-K →
Look up any company's CIK number →